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Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are overlapping, fatal neuro-
degenerative disorders in which the molecular and pathogenic basis remains poorly understood.
Ubiquitinated protein aggregates, of which TDP-43 is a major component, are a characteristic
pathological feature of most ALS and FTD patients. Here we use genome-wide linkage analysis in a large
ALS/FTD kindred to identify a novel disease locus on chromosome 16p13.3. Whole-exome sequencing
identiﬁed a CCNF missense mutation at this locus. Interrogation of international cohorts identiﬁed
additional novel CCNF variants in familial and sporadic ALS and FTD. Enrichment of rare protein-altering
CCNF variants was evident in a large sporadic ALS replication cohort. CCNF encodes cyclin F, a component
of an E3 ubiquitin–protein ligase complex (SCFCyclin F). Expression of mutant CCNF in neuronal cells
caused abnormal ubiquitination and accumulation of ubiquitinated proteins, including TDP-43 and a
SCFCyclin F substrate. This implicates common mechanisms, linked to protein homeostasis, underlying
neuronal degeneration.
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A
myotrophic lateral sclerosis (ALS) is a late-onset fatal
disorder characterized by the progressive degeneration of
upper and lower motor neurons. Approximately 10% of
ALS cases have a positive family history (familial ALS) and
appear clinically indistinguishable from sporadic ALS cases.
Mutations in several genes including SOD1, TARDBP, FUS,
UBQLN2, PFN1, OPTN, VCP, MATR3, TUBA4A and C9ORF72
account for approximately two-thirds of familial ALS and 5% of
sporadic ALS cases1–11. Other ALS families are not linked to
known loci and the cause of most sporadic ALS also remains
unknown. Upto 15% of ALS patients are also diagnosed with
frontotemporal dementia (FTD) and segregation of both ALS and
FTD may be seen within families, particularly those with
mutations in C9ORF72 (refs 7,8).
The aetiology of ALS remains poorly understood but recent
ALS gene discoveries are providing insight into pathological
disease mechanisms and are critical to the development of in vitro
and in vivo models to study pathogenesis. Coupling linkage
analysis with next-generation sequencing provides a powerful
approach for the identiﬁcation of novel ALS genes. Here we use
this approach to discover a pathogenic CCNF mutation in a large
ALS-FTD family. Additional CCNF mutations were identiﬁed in
diverse international familial ALS and FTD cohorts. Signiﬁcant
enrichment of novel and rare protein-altering variants in CCNF
was observed in a replication cohort of sporadic ALS cases
relative to controls. A hallmark pathological feature of most ALS
and FTD cases is the presence of abnormally ubiquitinated
proteins, particularly TDP-43, in neuronal cytoplasmic inclu-
sions12. We demonstrated that mutant cyclin F, encoded by
CCNF, resulted in abnormal ubiquitination and accumulation of
ubiquitinated proteins, including TDP-43.
Results
Linkage mapping implicates a new ALS locus on chromosome
16. To identify novel ALS loci, we performed two independent
genome-wide scans for linkage in an Australian multi-
generational family (FALS10, historically of UK ancestry)
comprising 10 individuals with ALS and/or FTD (Fig. 1a). The
family displays autosomal dominant inheritance of disease and
mutations in all known ALS genes were excluded. The ﬁrst
genome-wide scan for linkage, which used 10K Affymetrix
single-nucleotide polymorphism (SNP) arrays, implicated
candidate loci with maximum multipoint LOD scores 41.9 but
o3, on chromosomes 11p15.4-p14.3, 16p13.3-p12.3 and
20p13-p12.2, respectively (Supplementary Fig. 1b). The second
genome-wide scan for linkage, which used 539 microsatellite
markers, generated LOD scores 43.0 at a single candidate
region on chromosome 16 (maximum genome-wide two-point
LOD score of 3.16, y¼ 0, at D16S3065) that overlapped the
chromosome 16 interval identiﬁed by the initial, SNP-based,
linkage scan (Supplementary Fig. 1a). Fine mapping and
recombinant haplotype analysis using a dense coverage of
microsatellite markers spanning the chromosome 16 interval
reﬁned the minimal candidate region to 7.5Mb on chromosome
16p13.3 ﬂanked by D16S521 and D16S418, with a maximum
two-point LOD score of 3.24, y¼ 0, at D16S3082 (Supplementary
Table 1). Multipoint linkage analysis of the 7.5Mb disease
haplotype indicated LOD scores 43 across the entire linked
disease interval (Supplementary Fig. 1c). In summary, unbiased
genome-wide linkage analysis in family FALS10 identiﬁed a single
novel familial ALS/FTD locus on chromosome 16p13.3.
A missense mutation in CCNF in a large ALS/FTD family. Four
family members with ALS or FTD (FALS10, individuals II:10,
II:13, III:1 and III:15) were chosen for whole-exome sequencing.
The mean read depth for these patients was  119.3, with an
average of 6.01 109 base pairs sequenced per individual.
To identify candidate mutations, exome sequence variants were
annotated and ﬁltered (Supplementary Table 2) using the
following criteria: the variant was present in four affected family
members, resulted in altered amino-acid sequence, and was
absent from public SNP databases including dbSNP137, the 1000
Genomes Project (40.001 frequency, October 2011 release), the
NHLBI Exome Sequencing Project (ESP) exome variant server
(6,503 sequenced human exomes), and ExAC database (40.001
frequency). Of the two variants that remained following ﬁltering,
one was located within the linked region on chromosome 16p13.3
and the other lies in a region on chromosome 22 that was
excluded by linkage analysis (LOD scores o 2 for multiple
ﬂanking markers). The variant in the linked region lies in the
CCNF gene, leads to an A to G substitution at position 1,861 of
the coding DNA (c.1861A4G) and results in an amino-acid
substitution of serine with glycine at codon 621 at the protein
level (p.S621G). Sanger sequencing of 29 family members
demonstrated segregation of the mutation in all affected family
members for whom DNA was available (three ALS and one
FTD). We also genotyped the offspring of other ALS patients for
whom DNA was unavailable (deceased), and demonstrated
segregation of the mutation in a further three patients (that is,
obligate carriers, Fig. 1a,b). As such, we have shown segregation
of the CCNF c.1861A4G mutation in seven ALS patients from
family FALS10. The mutation was present in four at-risk family
members (three o40 years, one o60 years). This variant was
absent from 1,831 control individuals recruited from the same
population. This variant is present in the ExAC database as a
singleton (MAF¼ 8.629 10 6). It is important to note that the
ExAC database also includes other reported ALS/FTD mutations
as singletons (including SOD1, FUS and GRN). Here unbiased
whole-exome sequencing in family FALS10 identiﬁed two novel
missense variants as candidate pathogenic mutations, one of
which lies within the novel linked locus on chromosome 16p13.3
and segregated with disease.
CCNF variants in ALS/FTD from diverse geographic populations.
To determine whether mutations in CCNF are present in other
ALS and FTD patients, we used targeted sequencing, whole-
exome sequencing or whole-genome sequencing in the following
discovery cohorts: index cases from 75 Australian ALS families,
159 UK ALS families, 108 USA ALS families, 100 Canadian ALS
families, 99 Italian ALS families, 32 Japanese ALS families, 30
Spanish ALS families, 16 Irish ALS families, 283 Japanese
sporadic ALS cases, 168 French-Canadian sporadic ALS cases,
26 USA sporadic ALS cases, 49 USA ALS trios, 99 USA FTD
(FTLD-TDP) cases, 43 Australian FTD families and 29 Australian
sporadic FTD cases. In familial ALS and/or FTD patients, we
identiﬁed ﬁve additional novel missense mutations in CCNF
(Table 1). In sporadic ALS and/or FTD patients, we found 19
protein-altering variants in CCNF (missense, nonsense and
frameshift), including seven novel variants (Supplementary
Table 4). Sanger sequencing conﬁrmed all novel CCNF variants.
Most of the novel variants substitute amino acids that are highly
conserved across species (Fig. 1d). All variants were examined in
large control cohorts and data sets including: dbSNP; NHLBI ESP
Exome Variant Server, 1000 Genomes Project, ExAC, the
Japanese Human Genetic Variation Database and 967 Australian
control exomes (of European ancestry). Selected variants were
also tested in population-speciﬁc control cohorts from the UK,
USA, Canada and Japan. None of the familial mutations or novel
sporadic variants were present in genotyped controls and were
absent from the public databases (Table 1). The average age of
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disease onset in familial ALS cases with a CCNF mutation is
55.3±8.0 (Supplementary Table 3). Detailed clinical descriptions
are provided in the Supplemental Information. No clear
relationship was evident between the location of mutations and
clinical phenotype. Familial ALS/FTD mutations in CCNF were
present in the overall cohorts from these diverse geographic
populations at frequencies ranging from 0.6 to 3.3%, which is
comparable to the frequency of mutations in TARDBP (which
encodes TDP-43) and FUS that have been reported in familial
ALS cohorts13.
Enrichment of rare protein-altering variants in sporadic ALS.
To further evaluate whether rare protein-altering CCNF variants
are associated with sporadic ALS, we examined an independent
replication cohort of cases and controls. CCNF variants were
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Figure 1 | CCNF mutations in ALS-FTD identiﬁed following genetic linkage analysis and exome sequencing. (a) Pedigree of family FALS10. All family
members from whom DNAwas available for genotyping are indicated by either wild type (WT) for CCNF, or by mutation in CCNF (‘S621G’). Individuals with
ALS are represented by a black-ﬁlled symbol, individuals with FTD by a grey-ﬁlled symbol. Arrows indicate samples used for exome sequencing.
(b) Sequence traces of WT and c.1861A4G mutation identiﬁed in family FALS10. (c) Diagrammatic representation of cyclin F protein and the location of
novel mutations identiﬁed in this study. Cyclin F contains three functional modules within its protein structure. The F-box domain forms a ‘pseudocatalytic’
module, the two cyclin domains form the substrate recruitment module and the C terminus contains both a nuclear localization signal (NLS) and a PEST
sequence (short stretch of amino acids enriched in proline, glutamic acid, serine and threonine) that form the regulatory module16. (d) Multiple sequence
alignment of cyclin F across species showing evolutionary conservation of the substituted amino-acid residues (indicated by arrows). Sequences include
NP_001752.2 (human), NP_001252844.1 (chimpanzee), NP_031660.3 (mouse), NP_001093944.1 (rat), NP_001092340.1 (cow), NP_001079901.1 (frog)
and NP_996931.1 (zebraﬁsh).
Table 1 | ALS and/or FTD mutations in CCNF.
Amino-acid change Nucleotide change Exon Cohort Control samples (Sanger and exome) Public database MAF
Familial
p.S3G 7A4G 1 1/99 US FTLD-ALS 0/1038 US controls
0/657 AU controls
0/967 AU control exomes
Absent
p.K97R 290A4G 4 1/159 UK FALS 0/897 UK controls
0/967 AU control exomes
Absent
p.S195R 585T4G 6 1/30 SP FALS 0/967 AU control exomes Absent
p.S509P 1525T4C 13 1/99 IT FALS
1/168 CA SALS
0/361 CA controls
0/967 AU control exomes
Absent
p.S621G 1861A4G 16 1/75 AU FALS 0/864 AU Sanger controls
0/967 AU control exomes
Absent*
p.I772T 2315T4C 17 1/159 UK FALS 0/897 UK controls
0/967 AU control exomes
Absent
Sporadic
p.T181I 542C4T 6 1/283 JA SALS 0/514 JA controls
0/967 AU control exomes
Absent*
p.R392T 1175G4C 11 1/99 US FTLD 0/1038 US controls
0/967 AU control exomes
Absent
p.T543I 1628C4T 15 1/283 JA SALS 0/514 JA controls
0/967 AU control exomes
Absent
p.E624K 1870G4A 16 1/49 US SALS trios 0/801 AU Sanger controls
0/967 AU control exomes
Absent*
ALS, Amyotrophic lateral sclerosis; AU, Australian; CA, Canadian; ESP, Exome Sequencing Project; IT, Italian; MAF, minor allele frequency; SP, Spanish; UK, United Kingdom; US, USA.
CCNF accession NM_001761. Data were mined from whole exome or genome sequence data and validated by Sanger sequencing. Public databases include dbSNP; NHLBI ESP Exome Variant Server and
1000 Genomes Project.
*Variant was present as a singleton in ExAC, frequency of 8.6 10 6.
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identiﬁed in 611 Australian sporadic ALS cases and 1,424 cases
from the ALS Data Browser data set. For the control data set,
we used rare CCNF variants from the ExAC database (MAF
o0.0001). Variants were subject to analysis if they were con-
sidered functional (nonsense, missense or frameshift) and passed
quality ﬁltres (described in Methods). Fisher’s exact test revealed
an enrichment of rare protein-altering variants in CCNF among
sporadic ALS patients (1.39%) compared with controls (0.67%),
P¼ 6.58 10 4.
UPS dysfunction and ubiquitination of TDP-43. CCNF (also
called FBXO1) encodes the 786 amino-acid cyclin F protein
(Fig. 1c). Cyclin F is a member of the cyclin protein family,
but unlike most cyclins, it does not bind or activate a cyclin
dependent kinase (CDK)14. Cyclin F is also a member of the
F-box protein family characterized by an F-box motif that binds
directly to SKP1, which in turn recruits CUL1 to form a
SCF (SKP1-CUL1-F-box protein) E3 ubiquitin–protein ligase
complex (SCFCyclin F)15,16. E3s mediate the ubiquitination and
proteasomal degradation of target proteins and are an integral
component of the ubiquitin proteasome system (UPS).
Aberrant misfolded proteins are targeted for disposal by
protein degradation pathways including the UPS and autophagic–
lysosomal system, both of which are components of the complex
network that maintains protein homeostasis (proteostasis). The
accumulation of neuronal protein aggregates in ALS patients
implicates dysfunction of the proteostasis network through
inappropriate or inadequate response to aberrant proteins17. As
a ubiquitin–protein ligase, cyclin F catalyses the transfer of
activated ubiquitin to target proteins15. To investigate whether
the ALS/FTD-associated variants in cyclin F lead to proteostasis
dysfunction, we used the UPS reporter, GFPu, that consists of a 16
amino-acid degron (CL1, a speciﬁc substrate for the UPS), fused
to the carboxyl terminus of green ﬂuorescent protein (GFP)18.
The degron sequence ensures rapid degradation of the
GFP fusion through ubiquitin-mediated pathways, and the
accumulation of this GFP reporter indicates UPS impairment.
We conﬁrmed that GFPu signal correlates with UPS function in a
motor neuron-like cell line (NSC-34) by inhibiting proteasome
function using either the chemical inhibitor MG132, or
expression of a mutant huntingtin exon 1 fragment containing
an expanded polyQ sequence previously shown to inhibit the
proteasome19 (Supplementary Fig. 2). Next, we co-transfected the
NSC-34 cell line with GFPu and either mutant cyclin F or wild-
type cyclin F (Supplementary Table 4). Signiﬁcantly higher levels
of GFPu ﬂuorescence were observed for cyclin F with ALS/FTD-
associated variants, indicating UPS dysfunction (Fig. 2a). This
effect was independent of cyclin F expression levels (Fig. 2b).
To examine whether the signiﬁcant accumulation of GFPu arose
from the loss of proteasome activity or occurred upstream of the
proteasome, we used two separate ubiquitin-independent small
peptide 20S proteasome activity assays. These demonstrated that
the UPS dysfunction was not due to altered proteolysis in the
proteasome (Supplementary Fig. 3), consistent instead with the
dysfunction stemming from abnormal ubiquitination or transport
to the proteasome, mechanisms that are mediated, in part, by
cyclin F. Consistent with these observations, western blotting
conﬁrmed the presence of signiﬁcantly more ubiquitinated
proteins in neuronal cell lines expressing mutant cyclin F
(Fig. 3a,b). Collectively our data suggest that ALS/FTD-
associated variants in CCNF modify the activity of SCFCyclin F
resulting in overaccumulation of ubiquitinated proteins.
To speciﬁcally demonstrate this, we found higher levels of the
known SCFCyclin F target, RRM2 (Fig. 3a,b), including higher
levels of ubiquitinated RRM2 (Fig. 3c), in neuronal cells
expressing mutant cyclin F. Notably, we also observed
substantially elevated levels of ubiquitinated TDP-43 in
neuronal cells expressing mutant cyclin F (Fig. 3c).
Discussion
We performed whole-genome linkage analysis and whole-exome
sequencing in one of the largest ALS/FTD pedigrees to be
described in recent years. ALS/FTD was signiﬁcantly linked to a
single locus encompassing CCNF and exome sequencing
identiﬁed a single CCNF mutation that segregated with seven
affected family members. We extended mutation discovery and
rare variant analysis to ALS/FTD cohorts from diverse geographic
populations, most of European ancestry. Analysis in a replication
cohort showed a signiﬁcant enrichment of novel and rare protein-
altering CCNF variants in sporadic ALS patients. This suggests
that aberrant cyclin F plays a role in both familial and sporadic
ALS pathogenesis. Diagnosis of primary lateral sclerosis (PLS, an
upper motor neuron disease) in a mutation carrier suggests
that the spectrum of CCNF-linked motor neuron disease is wider
than ALS.
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Figure 2 | Mutant cyclin F impairs ubiquitin-mediated proteasomal
degradation. NSC-34 cells were co-transfected with GFPu and either wild
type or mutant cyclin F, tagged with mCherry. GFPu ﬂuorescence intensity
was analysed by ﬂow cytometry 48 h post transfection. (a) Plot of GFPu
ﬂuorescence intensity following ﬂow cytometry. A signiﬁcantly higher level
of GFPu ﬂuorescence was observed in cells expressing novel cyclin F
mutations (blue data points) when compared with those expressing wt
CCNF (red data points) WT v FALS/FTD P¼0.0017, d.f.¼ 11; WT v SALS/
FTD P¼0.001, d.f.¼ 7; two-tailed unpaired Student’s t-test). (b) The higher
level of GFPu ﬂuorescence was independent of the level of cyclin F as
quantiﬁed using mCherry signal—R-squared¼0.13. Red dashed lines
represent the WTmean. Data are represented as mean,±s.e.m. n¼ 3 (n is
one experiment consisting of the mean of 50,000 cells); **Po0.01. d.f.,
degrees of freedom.
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Neuronal accumulations of ubiquitinated TDP-43 are a major
pathological feature of almost all ALS cases, and the majority of
FTD cases. However, the mechanisms responsible for TDP-43
ubiquitination are poorly understood. We demonstrated that
ALS/FTD-associated variants in CCNF are responsible for
abnormal increases in ubiquitination of TDP-43 and may to be
responsible for wider changes in protein homeostasis. Further
studies can now commence to conﬁrm whether CCNF mutations
lead to aberrant misfolded proteins and the accumulation of
neuronal protein aggregates in ALS and FTD patients.
Abnormal protein homeostasis has been hypothesized to play a
role in ALS pathogenesis. Convincing genetic linkage to familial
ALS has also been shown for UBQLN2, which encodes
ubiquilin 2, a protein that physically associates with ubiquitin
ligases and proteasomes to mediate protein degradation14.
Ubiquilin-2-positive neuronal inclusions are seen in affected
motor neurons of some ALS and ALS/FTD patients, and
ALS-linked mutations in ubiquilin 2 have also been shown to
impair protein degradation mediated by the UPS4,20. Several
other molecules that are functionally linked with cellular protein
degradation pathways have also been associated with ALS
(reviewed by Ling et al.17). Putative ALS-associated variants
have been described in SQSTM1/p62, a ubiquitin binding protein
with roles in protein degradation via the proteasome and
autophagy. Interestingly, one of these SQSTM1/p62 variants
and two cyclin F mutations described here, lie in a PEST
sequence, a domain that is thought to act as a signal peptide for
protein degradation21. ALS mutations have also been described in
OPTN, an autophagic adaptor protein that binds substrates
targeted for degradation and delivers them to autophagosomes6.
OPTN-linked pathogenic mechanisms remain to be determined.
A VCP mutation linked to inclusion body myopathy with Paget’s
disease of the bone and frontotemporal dementia (IBMPFD)
impairs ER-associated degradation of ubiquitinated proteins from
the ER22. VCP mutations have also been described in ALS cases
but the mechanisms by which these lead to motor neuron
degeneration remain unclear10. There is also evidence that defects
in molecules functionally related to cyclin F play a role in other
neurodegenerative diseases. Mutations in the related F-box only
protein 7 gene (FBXO7) cause autosomal recessive, early-onset,
parkinsonian-pyramidal syndrome and lead to decreased stability
of the FBXO7 protein23. Similar to cyclin F, the F-box motif of
FBXO7 interacts directly with Skp1 to form the SCF E3
ubiquitin–protein ligase complex15. Furthermore, around 10%
of early-onset Parkinson’s disease cases are caused by mutations
in PARK2, which encodes Parkin, an E3-ubiquitin ligase.
Parkin mutations impair degradation of its substrates, leading
to accumulation of toxic products and eventually cell death24.
The known ALS proteins TDP-43 and FUS are capable of
assembling into stress granules in response to oxidative stress and
environmental insults, a process that is accelerated by ALS-linked
mutations (reviewed by Li et al.25). Indeed, stress granules have
been described as the crucibles of ALS pathogenesis25. Stress
granules play a role in messenger RNA homeostasis and form
during cellular stress, presumably to halt translation of
non-essential transcripts. TIA-1, a messenger RNA-binding
protein, translocates from the nucleus to seed stress granule
formation in the cytoplasm. It was recently demonstrated that
TIA-1 knockdown in mouse spinal cord and cerebellum led to
marked and consistent increase in the expression of CCNF26.
Like most known ALS-linked molecules, it remains to be
determined whether the functional consequences of CCNF
mutations lead to a toxic gain of function or dominant-negative
loss of function or haploinsufﬁciency. We found one CCNF
frameshift variant (p.L372fs) that did not segregate with disease,
suggesting that a dominant toxic gain of function may be required
for mutant CCNF pathogenicity.
Segregation of the mutation with disease was clearly established
in the large discovery family but could not be determined for
other familial mutations in the discovery cohort due to the
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Figure 3 | Increased ubiquitinated proteins in neuronal cell lines expressing mutant cyclin F. NSC-34 and Neuro-2a cells were transfected with wild-type
or mutant cyclin F (p.S621G) expression constructs, and cells were collected after 24 h. (a,b) Cells transfected with mutant cyclin F (p.S621G) show
increased levels (normalized to transfected cyclin F-mCherry) of ubiquitinated proteins and a known cyclin F–SCF complex target, RRM2 (Neuro-2a:
Ubiq/cyclin F, P¼0.025; RRM2/cyclin F, P¼0.020. NSC-34: Ubiq/cyclin F, P¼0.032; RRM2/cyclin F, P¼0.023; two-tailed unpaired Student’s t-test).
(c) Immunoprecipitation (IP) of ubiquitinated proteins from transfected Neuro-2a cells (wild-type and mutant cyclin F (p.S621G)) show elevated levels of
ubiquitinated RRM2 and TDP-43 in neuronal cells expressing mutant cyclin F. Full-length blots are presented in Supplementary Fig. 4. Data are represented
as mean±s.e.m. n¼ 3; *Po0.05.
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absence of DNA from other affected family members. This is now
typical for familial ALS/FTD cohort studies, as almost all
extended kindreds have been solved, leaving only single
probands. We cannot conclusively determine that the additional
novel familial CCNF mutations are the sole cause of disease,
however, most substitute highly conserved residues and led to
UPS dysfunction in vitro. Further resequencing of CCNF is
warranted in other ALS and FTD cohorts, particularly those of
European ancestry. Our data suggest that mutation of the
encoded E3 ubiquitin ligase caused abnormal ubiquitination,
implicating that common mechanisms, linked to protein home-
ostasis, underlie neurodegeneration in ALS and FTD. Additional
functional studies, including animal models, can now commence
to assess the pathogenic mechanism, and identify the targets of
the mutant SCFCyclin F complex. These target molecules may, in
turn, be considered candidate ALS and FTD genes.
Methods
Participants and samples. Patients, family members and unrelated controls were
recruited under informed written consent as approved by the institutional review
boards of Macquarie University, King’s College London, Imperial College London,
University of Massachusetts at Worcester, Stanford University, Emory University,
McGill University Health Center, University of New South Wales, Mayo Clinic,
Queen Elizabeth Hospital (South Birmingham Research Ethics Committee),
Beaumont Hospital, Hospital Universitario 12 de Octubre, Fundacio´n CIEN,
IRCCS Istituto Auxologico Italiano and Fondazione IRCCS Istituto Neurologico
‘C. Besta’, and the University of Tokyo. Patients were diagnosed with deﬁnite or
probable ALS according to El Escorial criteria27. Patients had previously been
screened for mutations/expansions in known ALS genes including TARDBP,
SOD1, FUS, UBQLN2, OPTN, VCP, PFN1 and C9ORF72. Formalin-ﬁxed,
parafﬁn-embedded cervical spinal cord sections from Australian patients and
neurologically normal controls were provided by New South Wales Tissue
Resource Centre (Sydney, Australia).
Genetic linkage analysis. Genomic DNA was extracted from peripheral blood
using standard protocols. For SNP-based genetic linkage analysis, genotyping
was undertaken using the Affymetrix GeneChip Mapping 10Kv2.0 XbaI Array
containing 10,204 SNP markers following the manufacturer’s instructions and
apparatus (Affymetrix, Santa Clara, CA, USA). The raw microarray feature
intensities were processed using the Affymetrix Genotyping Tools software package
(GCOS/GTYPE) to derive SNP genotypes, marker order and linear chromosomal
location. Parametric multipoint linkage analysis of SNP data was performed
using Merlin v1.1 with intermarker distances obtained from the Marshﬁeld
(http://research.marshﬁeldclinic.org/) and deCODE (http://www.decode.com/)
sex-averaged SNP linkage maps.
For microsatellite-based genetic linkage analysis, genotyping was performed by
deCODE genetics using 539 microsatellite markers spaced at an average of 8 cM.
Two-point and multipoint linkage analysis was performed using the FASTLINK
v4.1 program of the easyLINKAGE v5.08 package28,29 and graphed using R
package lodplot v1.2. All available family members were used for analysis.
Parameters for linkage analysis included autosomal dominant inheritance,
age-dependent penetrance (0–30 years, 1%; 31–40 years, 30%; 41–50 years, 50%;
51–60 years, 70%; 61–70 years, 85%,470 years, 90%), a disease allele frequency of
0.0001, equal male and female recombination, and equal marker allele frequencies.
For ﬁne mapping across the chr16p13.3 haplotype, control allele frequencies and,
where available, CEPH allele frequencies were used to calculate two-point and
multipoint LOD scores. Multipoint linkage analysis was performed under three
penetrance models including the age-dependent penetrance classes described
above, as well as 100 and 70% disease penetrance.
Sequencing and mutation analysis. Exomes were captured using TruSeq Exome
Enrichment kit or Agilent SureSelectXT Human All Exon V4. Paired-end
sequencing was performed using the Illumina HiSeq2000 instrument.
CCNF exons were sequenced using Fluidigm Access Array target enrichment
and the MiSeq sequencing platform (Illumina). Amplicon primers were designed
using the Fluidigim D3 Design Studio to produce 150 bp amplicons targeting the
exons of CCNF.
Validation and analysis of the CCNF mutations was performed by direct DNA
sequencing following PCR ampliﬁcation of coding exons (NM_001761). PCR
products were Sanger sequenced using Big-Dye terminator sequencing and an ABI
3730XL DNA analyser (Applied Biosystems).
SNP genotyping in control individuals was performed using a custom
TaqMan SNP genotyping assay according to the manufacturer’s instructions
(Life Technologies) and analysed using a Viia 7 real-time PCR system
(Life Technologies).
Control exome data from 967 neurologically healthy individuals of
predominantly Western European descent obtained from the Diamantina Institute,
University of Queensland (Diamantina Australian Control Collection).
Bioinformatics. Sequencing reads generated by the Illumina platform were aligned
to the hg19 human genome assembly using BWA v0.6.1 (ref. 30), variants were
called using SAMtools v0.1.16 (ref. 31) and annotated using ANNOVAR32.
Annotated variants were compared among affected family members and controls
using R v3.1.1 (http://www.R-project.org/)33. Filtering of variants was performed
using dbSNP (releases 131, 132, 134 and 137; https://www.ncbi.nlm.nih.gov/SNP/),
1000 Genomes Project (Nov 2010 release; http://www.1000genomes.org/) and the
ESP exome variant server (ESP6500 data release; http://evs.gs.washington.edu/EVS/).
Sequence reads generated by MiSeq were mapped to the hg19 human genome
assembly using BWA30. GATK34–36 was applied to mapped reads for realigning
and recalibration of base quality scores and variant calling. ANNOVAR32 was used
for annotation of variants.
Quality ﬁlters for rare variant enrichment analysis include read depth Z10 in
475% of all samples and genotype quality 420.
Conservation of cyclin F orthologues was examined by aligning sequences from
a variety of species (Entrez protein database; http://ncbi.nlm.nih.gov) using Clustal
Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/).
Plasmids and cloning. Expression constructs comprising wild type and
mutant CCNF cDNA fused with an N-terminal mCherry were developed using
pmCherry-C1-CCNF (Addgene, https://www.addgene.org/32975/) and Q5 Site-
Directed Mutagenesis kit (NEB) according to the manufacturer’s protocol. All
constructs were veriﬁed by DNA sequencing.
Antibodies. The following primary antibodies were used in this study: rabbit
polyclonal anti-cyclin F (cat # sc-952, Santa Cruz Biotechnology), mouse
monoclonal anti-TDP-43 antibody (cat # H00023435-M01, Abnova), rabbit
polyclonal anti-ubiquitin (Dako), mouse monoclonal anti-RRM2 (cat # ab57653,
Abcam), anti-b actin (cat # A5441 [AC-15], Sigma-Aldrich). All antibodies were
commercially sourced and validated according to the antibody data sheets.
Cell lines. Mouse NSC-34 (neuroblastoma/motor neuron-enriched primary spinal
cord hybrid) cells were provided by Prof Neil Cashman, University of Toronto.
Mouse neuroblastoma Neuro-2a cells, and human neuroblastoma SH-SY5Y cells
were from the ATCC repository (ATCC Product Nos. CCL-131 and CRL-2266).
Confocal microscopy. Confocal ﬂuorescence imaging was performed using a Leica
DM6000 upright laser-scanning confocal microscope with Leica application suite
advanced ﬂuorescence software. Images were acquired with a  63 (1.4 numerical
aperture) oil-immersion objective. Images were acquired using sequential mode to
avoid crosstalk between two dyes. Immunohistochemistry imaging was performed
with a Zeiss Axio Imager 2 with ZEN pro program, using a  40 objective.
Cell culture and transfection for UPS assays. NSC-34 cells were maintained
in DMEM (Sigma Aldrich) containing 100Uml 1 penicillin, 100mgml 1
streptomycin and 10% (v/v) heat-inactivated fetal bovine serum (Sigma Aldrich).
Cells were maintained in a humidiﬁed 37 C incubator with 5% CO2. For the UPS
assay and Enzo proteasome assay, NSC-34 cells were plated at a density of 50,000
cells per well in six-well plate. For the Abcam proteasome assay, NSC-34 cells were
plated at a density of 2,000 cells per well in 96-plate well plate. Transfections
were carried out using Lipofectamine LTX (Life Technologies) according to
manufacturer’s protocol. Transfections included 2.5 mg DNA for the UPS assay,
5 mg DNA for the Enzo proteasome assay or 0.1 mg DNA for the Abcam
proteasome assay.
Ubiquitinated protein immunoprecipitation. Co-transfected Neuro-2a cells were
lysed and total protein was extracted with sonication (10 s, Setting 3, Branson
Soniﬁer 450) in extraction buffer (1% (v/v) Nonidet P-40 in TBS (50mM Tris-HCl,
pH 7.5, 150mM NaCl) with protease inhibitor cocktail). Cellular debris was
pelleted at 18,000g (30min at 4 C). Protein concentration was estimated using
the BCA Protein Assay Reagent (Pierce Biotechnology). Typically, 3 mg of anti-
ubiquitin (Dako) per 500 mg of protein extract was used for immunoprecipitations.
Protein A/G magnetic beads (Pierce Biotechnology) were used to capture the
antibody:protein complex. Immunoprecipitates were washed with TBSþ 1% (v/v)
NP-40 (3 ) to remove non-speciﬁcally bound proteins, and then resuspended in
1 LDS buffer with 50mM DTT, and heated at 95 C for 10min.
UPS reporter assay and 20S proteasome activity assay. For the UPS
reporter assay, NSC-34 cells were cultured in six-well plates for 24 h, followed
by co-transfection with a UPS-speciﬁc degron GFPu and cyclin F constructs.
The GFPu reporter contains a CL1 sequence which signals ubiquitination and
degradation by the proteasome18,37. The resulting GFP signal is a reporter for rate
of protein degradation in the cell. Cells were collected 48 h post transfection by
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trypsin and resuspended in PBS (Sigma-Aldrich). In order to show the sensitivity
of GFPu construct, cells were either transfected with GFPu for 24 h followed
by MG132 (Calbiochem) treatment at various doses for a further 24 h or
co-transfected with GFPu and mCherry with or without MG132, or lastly
co-transfected with GFPu and either Httex125Q or Httex146Q and incubated for
48 h. The ﬂuorescent intensity GFP in collected cells was analysed using ﬂow
cytometry Becton Dickinson LSR II. At least 50,000 cells per treatment were
collected. Data were gated on mCherry-positive cells with an excitation at 541 nm
and an emission at 575 nm. The geometric mean of the GFP signal from this
population was collected with an excitation at 488 nm and an emission at 520 nm.
Data were from three independent experiments.
The proteasome enzymatic activity of cyclin F was measured using either
a 20S proteasome assay kit from Enzo Life Sciences or Abcam following the
manufacturer’s instructions. For the Enzo Life Sciences proteasome activity kit,
NSC-34 cells were transfected wild-type pmCherry-C1-CCNF or mutant
pmCherry-C1-CCNF in six-well plates and protein extract was generated by
freeze–thaw lysis 48 h post-transfection. Protein concentration was measured by
BCA protein assay (Thermo Scientiﬁc) and equal amount of protein was used in
the assay. The proteasome activity was measured by hydrolysis of a ﬂuorogenic
peptide substrate Suc–Leu–Leu–Val–Tyr–AMC (AMC: 7-amino-4-methylcoumarin).
The substrate is cleaved by the 20S proteasome and the release of free AMC
ﬂuorophore is used as an indication of proteolytic activity. The ﬂuorescent signal
was measured by FLUOstar OPTIMA ﬂuorescence plate reader (BMG Labtech)
with an excitation at 360 nm and an emission at 460 nm. The data were collected at
2-min interval for 50min. For the Abcam proteasome activity kit, NSC-34 cells
were transfected with wild-type pmCherry-C1-CCNF or mutant pmCherry-C1-
CCNF in 96-well plates for 48 h. A proteasome substrate Leu–Leu–Val–Tyr–R110
was added directly to the cells and incubated at 37 C for 1 h. The substrate is
cleaved by the 20S proteasome and the ﬂuorescent signal generated from the
cleavage is used as an indication of proteolytic activity. The ﬂuorescent signal was
measured by FLUOstar OPTIMA ﬂuorescence plate reader (BMG Labtech) with an
excitation at 490 nm and an emission at 525 nm.
Statistical analysis of in vitro assays. All statistical analyses were performed
using GraphPad Prism Software. Two-tail unpaired Student’s t-tests (Po0.05) were
used for grouped GFPu data (wild-type, cyclin F mutation (familial and sporadic)).
One-way analysis of variance with Dunnett’s multiple comparison tests were used
for comparison of GFPu levels in the presence of cyclin F variants, with wild type.
Statistical analyses of other in vitro assays were performed using two-tailed
unpaired Student’s t-tests (Po0.05). All values were mean±s.e.m. The data met
the assumptions of each speciﬁc statistical test. Variance was similar between
groups. Sample size was chosen based on results from pilot studies.
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